US Stock Insider Trading | Zai Lab disclosed one insider transaction on March 5

K-LinePoet · 2026-04-07T01:48:48+00:00

On March 5, 2026, Zai Lab (ZLAB) disclosed an insider transaction involving one of its executives. Amado Rafael sold 10k shares on March 3, 2026.【Recent Insider Transactions】| Disclosure Date | Position | Name | Transaction Date | Buy/Sell | Quantity | Price per Share/USD | Total Amount/USD || --- | --- | --- | --- | --- | --- | --- | --- || March 5, 2026 | Executive | Amado Rafael | March 3, 2026 | Sell | 10k | 17.38 | 173.8k || December 18, 2025 | Executive |

K-LinePoet

2026-04-07 01:48:48

March 5, 2026, ZaiDing Pharmaceutical (ZLAB) disclosed 1 corporate insider transaction. Executive Amado Rafael sold 10k shares on March 3, 2026.

【Recent Insider Transactions】

Disclosure date	Position	Name	Transaction date	Buy/Sell	Quantity	Price per share/USD	Total amount/USD
March 5, 2026	Executive	Amado Rafael	March 3, 2026	Sold	10k	17.38	173.8k
December 18, 2025	Executive	Edmondson Frazor Titus III	December 16, 2025	Sold	8,651	17.14	148.3k
November 25, 2025	Executive	Edmondson Frazor Titus III	November 21, 2025	Sold	14.3k	19.78	283.4k
November 4, 2025	Executive	Chen Yajing	November 3, 2025	Sold	240	26.83	6,439.44
October 3, 2025	Executive	Chen Yajing	October 2, 2025	Sold	456	34.25	15.6k
September 12, 2025	Executive	Smiley Joshua L	September 10, 2025	Bought	10k	28.91	289.1k
September 3, 2025	Director	Du Ying	August 29, 2025	Bought	644,400	1.20	7,253,000
September 3, 2025	Director	Du Ying	August 29, 2025	Sold	251.3k	32.59	81,905,000
August 19, 2025	Executive	Smiley Joshua L	August 18, 2025	Sold	6,641	36.24	240.6k
August 19, 2025	Executive	Edmondson Frazor Titus III	August 18, 2025	Sold	1,883	36.24	68.2k

【Company Profile】

ZaiDing Pharmaceutical Co., Ltd. is a holding company primarily engaged in biopharmaceuticals. The company is committed to addressing unmet medical needs in oncology, autoimmune diseases, infectious diseases, and central nervous system diseases by discovering, developing, and commercializing products. The company has a series of patent-candidate drugs ranging from the discovery stage to the late stages of clinical programs. These include “ZeLe,” “OPTUNE,” “QingLe,” “NiuZaiLe,” and “WeiWeiJia,” among others.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes